EATG » Access

Access

Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine

The latest battle over access to medicines is taking place in Ukraine, where Doctors Without Borders is urging Gilead Sciences to drop a court action that, if successful, would prevent…

Gilead donates Truvada to HIV trial patients

Gilead has donated 2,000 bottles of its Truvada (emtricitabine+tenofovir) to patients who took part in a UK clinical study that established its use in HIV prevention, so they can continue…

Separating myths from facts: Donor funding for the HIV response

This analysis from Health Gap describes the massive shortcomings in funding the HIV response globally, and the burden carried by so-called middle-income countries. "In July 2016, the Kaiser Family Foundation…

Analysis of why drug prices are so high in the USA

The study The High Cost of Prescription Drugs in the United States - Origins and Prospects for Reform by Aaron S. Kesselheim Jerry Avorn, and Ameet Sarpatwari discusses the reasons why medicine prices are often incomprehensibly high, and keep…

Georgia launches new national strategy to eliminate hepatitis C

TBILISI - The Georgian Government has approved a National Strategy for the Elimination of Hepatitis C during a cabinet session on Tuesday (August 16). The new campaign will run until…

Antiretroviral treatment scale-up and TB mortality in high TB/HIV burden countries: an econometric analysis

Abstract Introduction Antiretroviral therapy (ART) reduces mortality in patients with active tuberculosis (TB), but the population-level relationship between ART coverage and TB mortality is untested. We estimated the reduction in…

Are we losing our passion as AIDS activists?

We’ve come a long way since the days when fighting for LGBT rights demanded action such as the Stonewall Riots. Or a critical need for HIV medications prompted protests blocking traffic…

Access to treatment for hepatitis C virus infection: time to put patients first

Summary Sound health policy puts patients first. Antiviral regimens approved in 2014 revolutionised treatment of hepatitis C virus (HCV) infection. Most patients can now be cured. These new regimens, however,…

Why are hepatitis C patients treated differently by NHS England?

NHS England’s decision to cap access to National Institute for Health and Care Excellence (NICE) approved hepatitis C treatments has been attributed to their cost. These antiviral medicines have led…

PROUD study closes leaving participants with no access to PrEP

On 29 July 2016, the PROUD study website announced that the study will close without being able to continue to provide participants with oral PrEP. The press release blames…